Financhill
Buy
54

PDEX Quote, Financials, Valuation and Earnings

Last price:
$42.82
Seasonality move :
-1.93%
Day range:
$40.19 - $43.01
52-week range:
$16.84 - $70.26
Dividend yield:
0%
P/E ratio:
15.23x
P/S ratio:
2.23x
P/B ratio:
3.93x
Volume:
78.9K
Avg. volume:
66.3K
1-year change:
124.7%
Market cap:
$138.6M
Revenue:
$53.8M
EPS (TTM):
$2.79

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PDEX
Pro-Dex
$17.7M $0.47 23.84% 147.37% $54.00
ABT
Abbott Laboratories
$10.4B $1.07 6.07% 68.64% $140.22
BSX
Boston Scientific
$4.6B $0.67 18.78% 229.2% $116.20
OM
Outset Medical
$27.8M -$0.95 7.36% -90.13% $22.25
PODD
Insulet
$543.3M $0.79 25.32% -63.95% $323.70
SYK
Stryker
$5.7B $2.73 9.23% 43.24% $423.98
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PDEX
Pro-Dex
$42.49 $54.00 $138.6M 15.23x $0.00 0% 2.23x
ABT
Abbott Laboratories
$129.05 $140.22 $224.5B 16.74x $0.59 1.77% 5.33x
BSX
Boston Scientific
$102.95 $116.20 $152.3B 75.15x $0.00 0% 8.73x
OM
Outset Medical
$17.24 $22.25 $305.5M -- $0.00 0% 0.65x
PODD
Insulet
$314.46 $323.70 $22.1B 56.56x $0.00 0% 10.58x
SYK
Stryker
$387.53 $423.98 $148.1B 52.37x $0.84 0.85% 6.44x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PDEX
Pro-Dex
34.14% 0.505 11.31% 1.41x
ABT
Abbott Laboratories
21.34% 0.621 6.18% 1.27x
BSX
Boston Scientific
33.49% 1.029 7.48% 0.68x
OM
Outset Medical
35.65% 2.513 47.09% 6.60x
PODD
Insulet
56.03% 1.663 9.18% 3.24x
SYK
Stryker
44.5% 1.153 12.02% 0.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PDEX
Pro-Dex
$5.8M $3.6M 20.23% 29.31% 27.56% $574K
ABT
Abbott Laboratories
$5.9B $1.7B 23.5% 31.31% 18.43% $933M
BSX
Boston Scientific
$3.2B $937M 6.35% 9.57% 19.02% $277M
OM
Outset Medical
$11.1M -$16.4M -44.16% -140.06% -74.31% -$25.8M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
SYK
Stryker
$3.7B $872M 8.33% 14.2% 14.87% $127M

Pro-Dex vs. Competitors

  • Which has Higher Returns PDEX or ABT?

    Abbott Laboratories has a net margin of 18.81% compared to Pro-Dex's net margin of 12.79%. Pro-Dex's return on equity of 29.31% beat Abbott Laboratories's return on equity of 31.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    ABT
    Abbott Laboratories
    56.86% $0.76 $62.3B
  • What do Analysts Say About PDEX or ABT?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 27.09%. On the other hand Abbott Laboratories has an analysts' consensus of $140.22 which suggests that it could grow by 8.65%. Given that Pro-Dex has higher upside potential than Abbott Laboratories, analysts believe Pro-Dex is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    ABT
    Abbott Laboratories
    12 9 0
  • Is PDEX or ABT More Risky?

    Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.742, suggesting its less volatile than the S&P 500 by 25.819%.

  • Which is a Better Dividend Stock PDEX or ABT?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.77% to investors and pays a quarterly dividend of $0.59 per share. Pro-Dex pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PDEX or ABT?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Pro-Dex's net income of $3.3M is lower than Abbott Laboratories's net income of $1.3B. Notably, Pro-Dex's price-to-earnings ratio is 15.23x while Abbott Laboratories's PE ratio is 16.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.23x versus 5.33x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.23x 15.23x $17.4M $3.3M
    ABT
    Abbott Laboratories
    5.33x 16.74x $10.4B $1.3B
  • Which has Higher Returns PDEX or BSX?

    Boston Scientific has a net margin of 18.81% compared to Pro-Dex's net margin of 14.45%. Pro-Dex's return on equity of 29.31% beat Boston Scientific's return on equity of 9.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    BSX
    Boston Scientific
    68.84% $0.45 $33.6B
  • What do Analysts Say About PDEX or BSX?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 27.09%. On the other hand Boston Scientific has an analysts' consensus of $116.20 which suggests that it could grow by 12.87%. Given that Pro-Dex has higher upside potential than Boston Scientific, analysts believe Pro-Dex is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    BSX
    Boston Scientific
    23 4 0
  • Is PDEX or BSX More Risky?

    Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock PDEX or BSX?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or BSX?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Pro-Dex's net income of $3.3M is lower than Boston Scientific's net income of $674M. Notably, Pro-Dex's price-to-earnings ratio is 15.23x while Boston Scientific's PE ratio is 75.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.23x versus 8.73x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.23x 15.23x $17.4M $3.3M
    BSX
    Boston Scientific
    8.73x 75.15x $4.7B $674M
  • Which has Higher Returns PDEX or OM?

    Outset Medical has a net margin of 18.81% compared to Pro-Dex's net margin of -86.66%. Pro-Dex's return on equity of 29.31% beat Outset Medical's return on equity of -140.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    OM
    Outset Medical
    37.19% -$3.66 $264M
  • What do Analysts Say About PDEX or OM?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 27.09%. On the other hand Outset Medical has an analysts' consensus of $22.25 which suggests that it could grow by 29.06%. Given that Outset Medical has higher upside potential than Pro-Dex, analysts believe Outset Medical is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    OM
    Outset Medical
    3 2 0
  • Is PDEX or OM More Risky?

    Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PDEX or OM?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or OM?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Outset Medical quarterly revenues of $29.8M. Pro-Dex's net income of $3.3M is higher than Outset Medical's net income of -$25.8M. Notably, Pro-Dex's price-to-earnings ratio is 15.23x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.23x versus 0.65x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.23x 15.23x $17.4M $3.3M
    OM
    Outset Medical
    0.65x -- $29.8M -$25.8M
  • Which has Higher Returns PDEX or PODD?

    Insulet has a net margin of 18.81% compared to Pro-Dex's net margin of 6.22%. Pro-Dex's return on equity of 29.31% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About PDEX or PODD?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 27.09%. On the other hand Insulet has an analysts' consensus of $323.70 which suggests that it could grow by 2.94%. Given that Pro-Dex has higher upside potential than Insulet, analysts believe Pro-Dex is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    PODD
    Insulet
    14 3 0
  • Is PDEX or PODD More Risky?

    Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock PDEX or PODD?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or PODD?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Insulet quarterly revenues of $569M. Pro-Dex's net income of $3.3M is lower than Insulet's net income of $35.4M. Notably, Pro-Dex's price-to-earnings ratio is 15.23x while Insulet's PE ratio is 56.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.23x versus 10.58x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.23x 15.23x $17.4M $3.3M
    PODD
    Insulet
    10.58x 56.56x $569M $35.4M
  • Which has Higher Returns PDEX or SYK?

    Stryker has a net margin of 18.81% compared to Pro-Dex's net margin of 11.15%. Pro-Dex's return on equity of 29.31% beat Stryker's return on equity of 14.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
    SYK
    Stryker
    63.83% $1.69 $37.7B
  • What do Analysts Say About PDEX or SYK?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 27.09%. On the other hand Stryker has an analysts' consensus of $423.98 which suggests that it could grow by 9.41%. Given that Pro-Dex has higher upside potential than Stryker, analysts believe Pro-Dex is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    SYK
    Stryker
    13 9 0
  • Is PDEX or SYK More Risky?

    Pro-Dex has a beta of 0.365, which suggesting that the stock is 63.531% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

  • Which is a Better Dividend Stock PDEX or SYK?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.85% to investors and pays a quarterly dividend of $0.84 per share. Pro-Dex pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PDEX or SYK?

    Pro-Dex quarterly revenues are $17.4M, which are smaller than Stryker quarterly revenues of $5.9B. Pro-Dex's net income of $3.3M is lower than Stryker's net income of $654M. Notably, Pro-Dex's price-to-earnings ratio is 15.23x while Stryker's PE ratio is 52.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.23x versus 6.44x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.23x 15.23x $17.4M $3.3M
    SYK
    Stryker
    6.44x 52.37x $5.9B $654M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Stocks Are Recession-Proof?
What Stocks Are Recession-Proof?

Fears of a recession prevailed in Q2 2025 when the…

Which Stocks Are Recession-Proof?
Which Stocks Are Recession-Proof?

Fears of a recession prevailed in Q2 2025 when the…

Is Gartner a Safe Stock to Own?
Is Gartner a Safe Stock to Own?

Gartner (NYSE:IT) is among the world’s largest consulting, research and…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
70
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 44x

Alerts

Buy
57
RGC alert for May 14

Regencell Bioscience Holdings [RGC] is down 31.81% over the past day.

Buy
54
HALO alert for May 14

Halozyme Therapeutics [HALO] is down 24.57% over the past day.

Buy
91
COIN alert for May 14

Coinbase Global [COIN] is up 24.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock